个人简历

研究领域

"新型纳米载体给药系统

近期论文

Xuefei Zhou, Xiangrui Liu*, etc. Improving polyplex-mediated gene transfection efficiency by a selective CDK1 inhibitor RO-3306. Journal of Controlled Release (IF: 7.705) . Published online\r
\r
Xiangrui Liu, Rainer Wilcken, etc. Small-molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acid Research 2013 Jul 1;41(12):6034-44 (IF: 8.278)\r
\r
Xiangrui Liu, Shenhua Shi, etc. CDKI-71, a novel CDK9 inhibitor, is preferentially cytototoxic to cancer cells compared to flavopiridol. Int J Cancer. 2012 Mar 1;130(5):1216-26) (IF:6.198)\r
\r
Xiangrui Liu, Frankie Lam, etc. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Investigational new drugs 2012 Jun;30(3):889-97 (IF: 3.498) \r
\r
Xiangrui Liu, Jiabei Sun, etc. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. Journal of pharmacy and Pharmacology. 2012 Jun;64(6):775-82 (IF: 2.033)\r
\r
Xiang-Rui Liu, Ke-Chun Wu, etc. In Vitro and in Vivo Studies on Plasma to Blood Ratio of Paclitaxel in Human, Rabbit and Rat Blood Fractions. Bio. Pharm. Bull 2008 31(6)/1215-1220 (IF: 1.849)\r
\r
Xiangrui Liu, Shenhua Shi, etc. Cellular mechanism of a novel CDK9 inhibitor CDKI-71. EJC supplements 2010 8(5)/54/1 \r
\r
Xiangrui Liu, Jiabei Sun, etc. Pharmacokinetics, Biodistribution, Acute Toxicity and In Vivo Anti-tumour Efficacy of Paclitaxel Solid Dispersion Journal of pharmacy and Pharmacology. 2010 Oct; Vol. 62 (10) 1234-35 (IF: 2.033)\r
\r
Xiang-Rui Liu,Ke-Chun Wu, etc. A RP-HPLC method for determination of paclitaxel in its solid dispersion. Journal of Chinese Pharmaceutical Sciences 2007(16) 101-104\r
\r
Rainer Wilcken, Xiangrui Liu, etc. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc. 2012 Apr 18;134(15):6810-8 \r
\r
Hao Shao, Shenhua Shi, Shiliang Huang, Alison Hole, Abdullahi Y Abbas, Sonja Baumli, Xiangrui Liu, Frankie Lam, David W Foley, Peter M Fischer, Martin Noble, Jane A Endicott, Chris Pepper, Shudong Wang Substituted 4-(thiazol-5-yl)-2-(phenylamino) pyrimidines are highly active CDK9 inhibitors: synthesis, x-ray crystal structure, SAR and anti-cancer activities. Journal of Medicinal Chemistry 2013/01\r
\r
Pawel M Lukasik, Sherifa Elabar, Frankie Lam, Hao Shao, Xiangrui Liu, Abdullah Y Abbas, Shudong Wang. Synthesis and biological evaluation of imidazo [4, 5-b] pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents European journal of medicinal chemistry 2012